BioSpace News Archive

Ameresco, Inc. (NYSE:AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced that it will release its first quarter 2024 financial results after the close of the market on Tuesday, May 7, 2024.

Jaguar Health, Inc. announced the voting results of the Company’s Special Meeting of Stockholders held on April 9, 2024.

Auron Therapeutics announced two poster presentations at the American Association for Cancer Research Annual Meeting.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced the presentation of new preclinical data at the American Association for Cancer Research Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.

Medicenna Therapeutics Corp. presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 super-agonist, in patients with advanced solid tumors, at the 2024 Annual Meeting of the American Association for Cancer Research held in San Diego, CA, on April 9th, 2024.

Centene Corporation announced that its subsidiary, Meridian in Michigan, has been selected by the Michigan Department of Health and Human Services to continue to serve as a Medicaid health plan for the Comprehensive Health Care Program, which serves nearly 2 million Michiganders statewide.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET.

Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical results on the application of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for the treatment of solid tumors.

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”) today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

Onchilles Pharma announced today the presentation of new preclinical data for systemically delivered N17465 in an oral presentation and tumor-directed N17350 in a poster presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2024, taking place April 5 to 10 at the San Diego Convention Center.